Safinamide

Safinamide
Clinical data
Trade namesXadago, Onstryv
Other namesEMD-1195686, PNU-15774E;
(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl] methylamino]propanamide
AHFS/Drugs.comMonograph
Pregnancy
category
  • Fetal malformations in animal studies[1]
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability95%
Protein binding88–90%
MetabolismAmidases, glucuronidation
Elimination half-life20–30 hrs
Excretion76% Kidney, 1.5% faeces
Identifiers
  • N2-{4-[(3-fluorobenzyl)oxy]benzyl}-L-alaninamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.120.167 Edit this at Wikidata
Chemical and physical data
FormulaC17H19FN2O2
Molar mass302.349 g·mol−1
3D model (JSmol)
  • O=C(N)[C@@H](NCc2ccc(OCc1cccc(F)c1)cc2)C
  • InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1 checkY
  • Key:NEMGRZFTLSKBAP-LBPRGKRZSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Safinamide, sold under the brand name Xadago, is a medication used as treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.[4][5][7]

It was approved in the European Union in February 2015,[4] in the United States in March 2017,[5] and in Canada in January 2019.[2]

Medical uses

Safinamide is used to treat idiopathic Parkinson's disease as add-on for people taking a stable dose of levodopa (L-dopa) alone or in combination with other Parkinson drugs, to help with "off" episodes when levodopa stops working.[4][5][7]

Contraindications

Safinamide is contraindicated in people with severe liver impairment, with albinism, retinitis pigmentosa, severe diabetic neuropathy, uveitis and other disorders of the retina. Combination with other monoamine oxidase (MAO) inhibitors and pethidine is also contraindicated.[4]

It is not safe for women to take during pregnancy.[5] It is excreted in breast milk and the effects on infants are unknown.[4]

Adverse effects

Common adverse events in clinical trials (in more than 1% of people) included nausea, dizziness, tiredness, sleeplessness, orthostatic hypotension (low blood pressure), and headache. There was no significant difference in the occurrence of these effects between safinamide and placebo.[8][9]

Overdose

Expected overdose effects are hypertension (high blood pressure), orthostatic hypotension, hallucinations, psychomotor agitation, nausea, vomiting, and dyskinesia. In studies, a single person was suspected to have overdosed for a month; symptoms were confusion, drowsiness and mydriasis (dilation of the pupils) and subsided completely after the drug was discontinued. No specific antidote is available.[8]

Interactions

As a MAO inhibitor, safinamide can theoretically cause hypertensive crises, serotonin syndrome and other severe side effects when combined with other MAO inhibitors or with drugs that are known to interact with MAO inhibitors, such as pethidine, dextromethorphan, selective serotonin reuptake inhibitors (SSRIs), serotonin–noradrenaline reuptake inhibitors (SNRIs), tricyclic and tetracyclic antidepressants. An interaction with tyramine, a substance found in various foods, could be expected by the same reasoning but has been excluded in studies.[8]

Another theoretical interaction is with drugs with affinity to the transporter protein ABCG2 (also known as BCRP), such as pitavastatin, pravastatin, ciprofloxacin, methotrexate, and diclofenac; a study with the latter has shown no clinical relevance.[10] A study testing possible interactions with amidase inhibitors is part of the post-authorisation development plan.[1] There are no relevant interactions related to cytochrome P450 (CYP) liver enzymes, although one inactivation pathway of safinamide seems to be mediated by CYP3A4.[8]

Pharmacology

Mechanisms of action

Like the older antiparkinson drugs selegiline and rasagiline, safinamide is a selective monoamine oxidase B inhibitor, reducing degradation of dopamine; in contrast to the other two, its action is reversible. Safinamide also inhibits glutamate release[9][11] and dopamine and serotonin reuptake.[12] It binds to the sigma receptors as well, with IC50 values for binding inhibition of 19 nM for σ1 and 1,590 nM for σ2.[13] Additionally, it blocks sodium and calcium channels,[11][14] the relevance of which for its antiparkinson action is however unknown.[8]

Pharmacokinetics

Safinamide is absorbed quickly and nearly completely from the gut and reaches highest blood plasma concentrations after 1.8 to 2.8 hours. There is no relevant first-pass metabolism; total bioavailability is 95%. The substance is bound to plasma proteins to 88–90%.[8]

The metabolism is not well understood. The principal step is mediated by amidases which have not been identified, and produces safinamide acid (NW-1153). Other relevant metabolites are O-debenzylated safinamide (NW-1199),[10] the N-dealkylated amine which is then oxidized to a carboxylic acid (NW-1689), and the glucuronide of the latter.[8][15] In tests with liver microsomes, dealkylation seemed to be mediated by CYP3A4, but other CYP enzymes appear to be involved as well. Safinamide acid binds to the organic anion transporter 3 (OAT3), but this has probably no clinical relevance. Safinamide itself transiently binds to ABCG2. No other transporter affinities have been found in preliminary studies.[8]

Safinamide is eliminated, mainly (>90%) in form of its metabolites, via the kidney, with an elimination half-life of 20 to 30 hours. Only 1.5% are found in the stool.[8]

Metabolism pathways of safinamide.[10][15] Enzymes: CYP = cytochrome P450, MAO-A = monoamine oxidase A, ALDH = aldehyde dehydrogenases, UGT = UDP-glucuronosyltransferases. Gluc = acyl glucuronide.

History

The compound was originally discovered at Farmitalia-Carlo Erba,[16] which was acquired by Pharmacia in 1993. In 1995, Pharmacia merged with Upjohn. Safinamide was first disclosed in 1998.[17] In the course of a major restructuring in the same year, all rights for safinamide were transferred to the newly formed company Newron Pharmaceuticals, which developed the drug until it was sold to Merck KGaA in 2006.[18]

In 2007, a Phase III clinical trial was started, scheduled to run until 2011.[19] In October 2011 Merck, now Merck-Serono, announced that they would give all rights to develop the compound back to Newron because they wanted to prioritise other projects and had corrected their estimates for safinamide's market potential downwards.[20]

The US Food and Drug Administration (FDA) refused to file Newron's application in 2014 on formal grounds.[21] Newron re-applied in December 2014.[22] In spring 2015, following a commercial agreement between Newron and the Italian pharmaceutical company Zambon, the European Medicines Agency (EMA) approved the drug.[23] In the following years, the drug has been launched in several European countries.[24] Safinamide is the first antiparkinson medication to be approved for ten years.[25] Safinamide was approved by US FDA in March 2017 for people with Parkinsons taking levodopa/carbidopa during "off" episodes.[26][27]

Research

Potential additional uses might be restless legs syndrome (RLS) and epilepsy.[28] Safinamide was being tested in Phase II trials in 2008, but no results are available. When used as an adjunct to parkinsonian medication, safinamide was found to be efficacious in reducing pain in PD.[29]

In experiments with rats (but not in those with monkeys), retinopathies have been observed.[1][25]

References

  1. ^ a b c "Summary of the risk management plan (RMP) for Xadago (safinamide)" (PDF). European Medicines Agency. January 2015.
  2. ^ a b "Onstryv Product information". Health Canada. 25 April 2012. Retrieved 21 July 2019.
  3. ^ "Summary Basis of Decision (SBD) for Onstryv". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  4. ^ a b c d e f "Xadago - Summary of Product Characteristics". UK Electronic Medicines Compendium. 1 February 2017. Retrieved 2 April 2017.
  5. ^ a b c d e "Safinimide label" (PDF). FDA. March 2017. Retrieved 2 April 2017. See FDA index page for NDA 207145 for updates.
  6. ^ "Xadago EPAR". European Medicines Agency (EMA). 24 February 2015. Retrieved 27 August 2024.
  7. ^ a b Perez-Lloret S, Rascol O (2016). "The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease". Expert Review of Neurotherapeutics. 16 (3): 245–258. doi:10.1586/14737175.2016.1150783. hdl:11336/41809. PMID 26849427. S2CID 37787896.
  8. ^ a b c d e f g h i Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
  9. ^ a b Spreitzer H (14 April 2014). "Neue Wirkstoffe – Safinamid". Österreichische Apothekerzeitung (in German) (8/2014): 30.
  10. ^ a b c "Summary of Product Characteristics for Xadago" (PDF). European Medicines Agency. 24 February 2015.
  11. ^ a b Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. (October 2006). "Safinamide: from molecular targets to a new anti-Parkinson drug". Neurology. 67 (7 Suppl 2): S18–S23. doi:10.1212/wnl.67.7_suppl_2.s18. PMID 17030736. S2CID 26420481.{{cite journal}}: CS1 maint: overridden setting (link)
  12. ^ Fabbri M, Rosa MM, Abreu D, Ferreira JJ (December 2015). "Clinical pharmacology review of safinamide for the treatment of Parkinson's disease". Neurodegenerative Disease Management. 5 (6): 481–496. doi:10.2217/nmt.15.46. PMID 26587996.
  13. ^ Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, et al. (March 1999). "Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound". The Journal of Pharmacology and Experimental Therapeutics. 288 (3): 1151–1159. PMID 10027853.{{cite journal}}: CS1 maint: overridden setting (link)
  14. ^ Pevarello P, Bonsignori A, Caccia C, Amici R, McArthur RA, Fariello RG, et al. (September 1999). "Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants". Bioorganic & Medicinal Chemistry Letters. 9 (17): 2521–2524. doi:10.1016/s0960-894x(99)00415-1. PMID 10498200.{{cite journal}}: CS1 maint: overridden setting (link)
  15. ^ a b Krösser S, Marquet A, Gallemann D, Wolna P, Fauchoux N, Hermann R, et al. (December 2012). "Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects". Biopharmaceutics & Drug Disposition. 33 (9): 550–559. doi:10.1002/bdd.1822. PMID 23097240. S2CID 12986951.
  16. ^ Pevarello P, Varasi M (2018). "Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson's Disease". In Fischer J, Klein C, Childers WE (eds.). Successful Drug Discovery. Vol. 3. pp. 383–415. doi:10.1002/9783527808694.ch14. ISBN 9783527808694.
  17. ^ Pevarello P, Bonsignori A, Dostert P, Heidempergher F, Pinciroli V, Colombo M, et al. (February 1998). "Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives". Journal of Medicinal Chemistry. 41 (4): 579–590. doi:10.1021/jm970599m. PMID 9484507.{{cite journal}}: CS1 maint: overridden setting (link)
  18. ^ "Wichtigste Ergebnisse der Langzeitstudie mit Safinamid als Begleittherapie zu Levodopa bei Parkinson im fortgeschrittenen Stadium" [Major results from the long-term study of safinamide as add-on to levodopa for late-stage Parkinson] (Press release) (in German). Merck KGaA. 4 November 2010. Archived from the original on 11 June 2011.
  19. ^ "Study of Safinamide in Early Parkinson's Disease as Add-on to Dopamine Agonist (MOTION)". PDtrials.org. Archived from the original on 1 January 2011.
  20. ^ "Merck Returns Rights for Safinamide to Newron" (Press release). Merck Group. 21 October 2011.
  21. ^ "Information about FDA Refusal to File" (Press release). Newron. 29 July 2014. Archived from the original on 4 March 2016. Retrieved 22 September 2016.
  22. ^ "Information about FDA re-application" (PDF) (Press release). Newron. 29 December 2014. Archived from the original (PDF) on 4 March 2016. Retrieved 22 September 2016.
  23. ^ "Xadago EPAR Public assessment report" (PDF). European Medicines Agency. 18 December 2014.
  24. ^ "Parkinson, Zambon annuncia l'arrivo in Italia di safinamide" [Parkinson, Zambon announces the arrival of safinamide in Italy]. Aboutpharma (in Italian). 29 February 2016.
  25. ^ a b Klement A (18 July 2016). "Xadago". Österreichische Apothekerzeitung (in German) (15/2016): 10.
  26. ^ "FDA approves drug to treat Parkinson's disease" (Press release). Food and Drug Administration. 21 March 2017.
  27. ^ "After an odyssey of setbacks, FDA finally green-lights Newron's Parkinson's drug Xadago". Endpoints News. 21 March 2017. Retrieved 21 March 2017.
  28. ^ Chazot PL (July 2007). "Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome". Current Opinion in Investigational Drugs. 8 (7): 570–579. PMID 17659477.
  29. ^ Qureshi AR, Rana AQ, Malik SH, Rizvi SF, Akhter S, Vannabouathong C, et al. (2018). "Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis". Neuroepidemiology. 51 (3–4): 190–206. doi:10.1159/000492221. PMID 30153669.{{cite journal}}: CS1 maint: overridden setting (link)

Read other articles:

Douglas Costa

Douglas Costa Costa bermain untuk Brasil pada 2018Informasi pribadiNama lengkap Douglas Costa de Souza[1]Tanggal lahir 14 September 1990 (umur 33)Tempat lahir Sapucaia do Sul, BrasilTinggi 172 cm (5 ft 8 in)[2]Posisi bermain GelandangInformasi klubKlub saat ini Bayern München(pinjaman dari Juventus)Nomor 11Karier junior2001–2002 Novo Hamburgo2002–2008 GrêmioKarier senior*Tahun Tim Tampil (Gol)2008–2010 Grêmio 29 (2)2010–2015 Shakhtar Donetsk 141...

 

 

العلاقات المارشالية الشمال مقدونية

العلاقات المارشالية الشمال مقدونية جزر مارشال شمال مقدونيا   جزر مارشال   شمال مقدونيا تعديل مصدري - تعديل   العلاقات المارشالية الشمال مقدونية هي العلاقات الثنائية التي تجمع بين جزر مارشال وشمال مقدونيا.[1][2][3][4][5] مقارنة بين البلدين هذه م...

 

 

Paolo Di Stefano

Di Stefano nel 2012 Paolo Di Stefano (Avola, 1956) è uno scrittore e giornalista italiano. Indice 1 Biografia 2 Opere 2.1 Poesie 2.2 Romanzi 2.3 Racconti 2.4 Reportage 2.5 Altre pubblicazioni 3 Premi e riconoscimenti 4 Note 5 Altri progetti 6 Collegamenti esterni Biografia È cresciuto a Lugano, in Svizzera. Si è laureato in Filologia romanza con Cesare Segre a Pavia. Dopo una breve esperienza di ricerca universitaria, ha lavorato come giornalista al Corriere del Ticino e a la Repubblica, e...

ويليام-ماتيو دوماس

ويليام-ماتيو دوماس   معلومات شخصية الميلاد 23 نوفمبر 1753 [1][2]  مونبلييه  الوفاة 16 أكتوبر 1837 (83 سنة) [1][2]  باريس  مواطنة فرنسا  مناصب الحياة العملية المهنة سياسي،  ومؤرخ عسكري،  ومترجم،  وضابط،  وعسكري  اللغات الفرنسية  الخدمة العس�...

 

 

كارل فريدريش غاوس

كارل فريدريش غاوس (بالألمانية: Carl Friedrich Gauß)‏    معلومات شخصية اسم الولادة (بالألمانية: Johann Carl Friedrich Gauß)‏  الميلاد 30 أبريل 1777 [1][2][3][4][5][6][7]  براونشفايغ[8][1][9]  الوفاة 23 فبراير 1855 (77 سنة) [1][2][3][4][5][6] ...

 

 

William Francis Bartlett

Union Army general William Francis BartlettBornJune 6, 1840Haverhill, MassachusettsDiedDecember 17, 1876(1876-12-17) (aged 36)Pittsfield, MassachusettsBuriedPittsfield Cemetery, Pittsfield, MassachusettsAllegianceUnited States of AmericaUnionService/branchUnited States ArmyUnion ArmyYears of service1861–1866Rank Brigadier General Brevet Major GeneralUnit4th Massachusetts Infantry Battalion20th Massachusetts InfantryCommands held 49th Massachusetts Infantry 57th Massachusetts I...

5-IAI

Chemical compound NRG-5 redirects here. For the compact food biscuit used for disaster relief, see BP-5 Compact Food. 5-IAIClinical dataPregnancycategory ? Routes ofadministrationOral, Insufflated, RectalATC codenoneLegal statusLegal status BR: Class F2 (Prohibited psychotropics)[1] DE: NpSG (Industrial and scientific use only) UK: Under Psychoactive Substances Act In general: uncontrolled Identifiers IUPAC name 5-iodo-2,3-dihydro-1H-inden-2-amine CAS Number132367-...

 

 

The Saint (TV series)

British thriller series This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article possibly contains original research. Please improve it by verifying the claims made and adding inline citations. Statements consisting only of original research should be removed. (August 2023) (Learn how and when to remove this message) This article needs additional citations for verification. Please hel...

 

 

Daylife

This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (March 2015) (Learn how and when to remove this message) DaylifeType of siteB2B cloud media servicesAvailable inEnglishFounded2006Dissolved2016OwnerNewsCredCreated byDaylife, IncURLhttp://daylife.comCommercialYesRegistrationNot requiredLaunchedJan 2006Curr...

Rover's Morning Glory

Hot talk radio show This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Rover's Morning Glory – news · newspapers · books · scholar · JSTOR (August 2015) (Learn how and when to remove this message) Rover's Morning GloryGenreHot talkRunning time4 hrs. (weekdays, 6:00 am–10:00 am)[1]Country of origi...

 

 

乌克兰总理

 烏克蘭總理Прем'єр-міністр України烏克蘭國徽現任杰尼斯·什米加尔自2020年3月4日任命者烏克蘭總統任期總統任命首任維托爾德·福金设立1991年11月后继职位無网站www.kmu.gov.ua/control/en/（英文） 乌克兰 乌克兰政府与政治系列条目 宪法 政府 总统 弗拉基米尔·泽连斯基 總統辦公室 国家安全与国防事务委员会 总统代表（英语：Representatives of the President of Ukraine） 总...

 

 

التايكوندو في الألعاب الأولمبية الصيفية

التايكوندو في الألعاب الأولمبية الصيفيةالهيئة الإداريةالاتحاد العالمي للتايكوندوالمنافسات8 (رجال: 4; سيدات: 4)الألعاب 1896 1900 1904 1908 1912 1920 1924 1928 1932 1936 1948 1952 1956 1960 1964 1968 1972 1976 1980 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020 قائمة الفائزين بالميداليات ادرجت التايكوندو في الألعاب الأولمبية الصيفية...

جورج باول

  لمعانٍ أخرى، طالع جورج باول (توضيح). هذه المقالة تحتاج للمزيد من الوصلات للمقالات الأخرى للمساعدة في ترابط مقالات الموسوعة. فضلًا ساعد في تحسين هذه المقالة بإضافة وصلات إلى المقالات المتعلقة بها الموجودة في النص الحالي. (يناير 2019) هذه المقالة يتيمة إذ تصل إليها مقالا�...

 

 

Земире (опера)

ОпераЗемире Композитор Тигран Чухаджян Либреттист Тигран Келамджян Жанр феерия Действий 4 действий Год создания 1890 Первая постановка 12 апреля 1891 Место первой постановки Константинополь Земире — опера Тиграна Чухаджяна. Согласно «Краткой истории оперы», премьера «Зем�...

 

 

Kurt Elling

American jazz singer and songwriter Kurt EllingBackground informationBorn (1967-11-02) November 2, 1967 (age 56)Chicago, Illinois, U.S.GenresJazzOccupation(s)Singer, composerYears active1995–presentLabelsBlue Note, Naim, Concord Jazz, Cuneiform, Okeh, Edition RecordsWebsitekurtelling.comMusical artist Kurt Elling (born November 2, 1967) is an American jazz singer and songwriter. Born in Chicago, Illinois, and raised in Rockford, Elling became interested in music through his father, who...

علي شمخاني

علي شمخاني (بالفارسية: علی شمخانی)‏  وزارة الدفاع ودعم القوات المسلحة في المنصب19 أغسطس 1997 – 24 أغسطس 2005 الرئيس محمد خاتمي معلومات شخصية الميلاد 29 سبتمبر 1955 (العمر 68 سنة)الأهواز، إيران الجنسية إيراني الديانة إسلام الحياة العملية المدرسة الأم جامعة تشمران الأهوازية المهن�...

 

 

Carlo Azeglio Ciampi

President of Italy from 1999 to 2006 This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Carlo Azeglio Ciampi – news · newspapers · books · scholar · JSTOR (September 2016) (Learn how and when to remove this message) Carlo Azeglio CiampiOfficial portrait, 1999President of ItalyIn office18 May 1999 – 1...

 

 

The Lord of the Rings: The Two Towers (soundtrack)

2002 soundtrack album by Howard Shore The Lord of the Rings: The Two Towers: Original Motion Picture SoundtrackSoundtrack album by Howard ShoreReleased10 December 2002 (2002-12-10)GenreSoundtrackLength72:4677:09 (limited edition)LabelRepriseProducerHoward ShoreMiddle Earth film series soundtrack chronology The Lord of the Rings: The Fellowship of the Ring(2001) The Lord of the Rings: The Two Towers: Original Motion Picture Soundtrack(2002) The Lord of the Rings: The Return ...

2010 Adelaide Thunderbirds season

Adelaide Thunderbirds season Adelaide Thunderbirds2010 seasonHead coachJane Woodlands-ThompsonAsst. coachesLisa AlexanderJudy GreenwoodManagerCatherine ForemanCo-captainsNatalie von BertouchMo'onia GerrardVice-captainSharni LaytonMain venueETSA ParkSeason resultsWins–losses11–4Regular season2ndFinals placing1st Team colours Adelaide Thunderbirds seasons← 2009 2011 → The 2010 Adelaide Thunderbirds season saw Adelaide Thunderbirds compete in the 2010 ANZ Champions...

 

 

أنطونيو ليرة

هذه المقالة يتيمة إذ تصل إليها مقالات أخرى قليلة جدًا. فضلًا، ساعد بإضافة وصلة إليها في مقالات متعلقة بها. (أكتوبر 2019) أنطونيو ليرة معلومات شخصية تاريخ الميلاد 13 نوفمبر 1909   تاريخ الوفاة 23 أغسطس 1963 (53 سنة)   الجنسية البرازيل  الحياة العملية المهنة منافس ألعاب قوى  ال...